In May 2013, the American Psychiatric Association published the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders, and one of its most contested revisions was the elimination of the bereavement exclusion for major depressive disorder. Before that change, a clinician could not formally diagnose someone with major depression if their symptoms had emerged within two months of losing a loved one. Grief, the logic went, was its own category – not a mental illness, but a human response that deserved its own lane. The new manual collapsed that lane. And the argument has been raging ever since.
My position is this: the critics are worried about the wrong thing. The risk of under-treating genuine clinical depression in grieving people is far more serious than the risk of over-diagnosing people who are sad. The question isn’t whether grief is normal – it is. The question is whether being bereaved should legally protect someone from receiving a diagnosis they actually meet the criteria for. I don’t think it should.
The Rule That Used to Block the Diagnosis
To understand what changed, you have to understand what the old exclusion actually did. Under the DSM-IV (the previous edition), a clinician who saw a recently bereaved patient presenting with low mood, appetite changes, sleep disruption, and difficulty functioning could not diagnose that patient with major depressive disorder if those symptoms had appeared within two months of the bereavement. The clock was the judge. Grief was granted immunity, no matter how severe the presentation.
The removal of this exclusion was perhaps the most controversial single change from DSM-IV to DSM-5, and critics wasted no time arguing that it would “medicalize” ordinary grief and encourage the over-prescription of antidepressants. That’s an argument worth taking seriously. Nobody wants a devastated widow handed a prescription on week three when what she needs is time, community, and the chance to feel the loss without interference.
But supporters of the DSM-5’s decision argued there was no clinical or scientific basis for excluding patients from a diagnosis of major depression simply because the condition had its onset shortly after the death of a loved one. That argument has more force than it’s often given credit for. Loss doesn’t inoculate the brain against a depressive episode. For some people, it’s the very thing that tips them into one.
The Case Against: Grief Is Not a Disease
The most prominent voice against the DSM-5 change has been Allen Frances, a psychiatrist who chaired the DSM-IV taskforce – the very committee that maintained the bereavement exclusion in the first place. Frances has argued that the DSM-5’s approach “confuses mental disorder with the everyday sadness, anxiety, grief, disappointments, and stress responses that are an inescapable part of the human condition.” He’s a credible critic precisely because he spent years inside the system he’s now warning against.
The specific concern is that the DSM-5 would allow a diagnosis of major depression almost immediately after the loss of a loved one – meaning people now considered to be experiencing normal grief would instead receive a mental disorder label. Frances has been vocal about the downstream consequences: more prescriptions, more stigma, and an erosion of the cultural understanding that grief is something people go through, not something they have wrong with them.
The critique is also clinical. Eliminating the bereavement exclusion would result in an increasing number of people with normal grief being inappropriately diagnosed with major depressive disorder after only two weeks of depressive symptoms. A fortnight is, in any honest account, not long enough to conclude that someone whose spouse just died has a mental disorder. Two weeks of dark, terrible, barely-functional sadness after losing a person you loved for thirty years is not pathology. It’s proportion.
I understand this argument. I even find parts of it compelling. Grief has a dignity that clinical language can strip away. The person sobbing in the parking lot three weeks after their mother’s funeral is not broken. They are heartbroken. Those are different things.
Why I Still Think the Change Was Right
And yet. The bereavement exclusion had a structural flaw that its defenders have consistently underweighted: it protected a category rather than a person.
While bereavement-related grief and major depression share some features, they are distinct and distinguishable conditions – but bereavement does not immunize the patient against a major depressive episode, and is in fact a common trigger of clinical depression. A clinician who sees a bereaved patient at week three is not required, under the DSM-5, to diagnose major depression. They are now able to make that diagnosis if the full clinical picture warrants it. One scenario describes professional guidance; the other describes clinical judgment. They are not the same thing.
The DSM-5 criteria merely allow the diagnosis of major depressive disorder when a recently bereaved person meets all required symptom, severity, duration, and impairment criteria for MDD. Nothing in the manual compels that diagnosis. The exclusion’s critics sometimes write as if removing it opened the floodgates to automatic labeling of anyone who cries at a funeral. What actually happened is that a categorical exemption was replaced by a clinical judgment call – and clinical judgment is where medicine should be operating.
As proponents of the change argued, the harm that may follow a missed diagnosis of major depression in a bereaved person outweighs the harm of occasional over-diagnosis. The debate often focuses on the theoretical person who gets over-diagnosed and handed antidepressants they don’t need. Far less attention goes to the actual people – and they exist, in significant numbers – who were genuinely depressed during bereavement but couldn’t be formally diagnosed, couldn’t access insurance-covered treatment, and couldn’t be appropriately referred because the manual said their grief didn’t count yet.
The concern about stigma is real. A grieving patient receiving a mental disorder label carries costs. But clinicians may also unnecessarily withhold treatment from those who genuinely need it – and that cost is just as real, and far less discussed.
The Line That’s Actually Hard to Draw
The honest version of this debate is not about whether grief can become clinical depression. A considerable number of bereaved individuals reach the five-symptoms-for-two-weeks threshold that satisfies diagnostic criteria for major depressive disorder, and many experience clinically significant distress or role impairment – but their depression may resolve over time without treatment and may not follow the chronic, recurrent course typical of MDD. Some people in the worst pain of their lives will get better without intervention. Some won’t. Distinguishing between them is genuinely hard.
The overlap of symptoms between intense normal grief and major depressive disorder creates a real false-positive problem, where depressions that are part of normal bereavement may be misdiagnosed as MDD. The solution isn’t a blanket rule that prevents diagnosis. The solution is better clinical training in distinguishing between the two – and better tools to help clinicians make that call. Removing the exclusion forces clinicians to actually make a judgment, rather than defaulting to a time-based technicality.
The DSM-5 itself acknowledges this complexity. Clinicians are offered guidance on distinguishing major depression from both normal and pathological bereavement, with features like self-loathing, a pervasive inability to function, and suicidal ideation serving as indicators of major depression in addition to grief. This isn’t a system designed to pathologize sadness. It’s a system trying, imperfectly, to catch the people who are drowning in what looks like grief but is something else.
When Grief Becomes Something Else Entirely
The broader picture around grief and the grief depression diagnosis also changed significantly in 2022, and this part of the story is often left out of the conversation. In March 2022, prolonged grief disorder was added as a mental disorder in the DSM-5-TR – the text revision of the DSM-5. This is a separate and distinct diagnosis from major depression, and its inclusion actually represents something the critics of the 2013 change had been arguing for: a grief-specific category that acknowledges bereavement can produce its own form of severe, lasting impairment without needing to borrow the framework of depression.
Prolonged grief disorder is characterized by intense and persistent grief symptoms that are not only distressing in themselves but also associated with significant problems in functioning. In the DSM-5-TR, prolonged grief disorder is not categorized under depressive disorders – it sits in the chapter on trauma- and stressor-related disorders. This is a meaningful distinction. It says: this is its own thing. It’s not depression wearing a different name.
Prolonged grief disorder affects roughly 10 percent of bereaved survivors, though rates vary depending on the population studied and the definitions used. For that one in ten who don’t move through loss but get stuck in it, having a named, recognized diagnosis matters. It opens the door to targeted treatment. The DSM-5-TR requires that the loss occurred at least 12 months prior to diagnosis – a built-in protection against the premature labeling that critics of the 2013 change feared most.
Read More: Do Dogs Know They’re Dying? Signs, Euthanasia & Grief
The Strongest Counterargument, Honestly Stated
I want to be fair to the critics because their strongest argument isn’t about false positives – it’s about power. As a 2017 analysis in the AMA Journal of Ethics argued, the DSM-5 Task Force’s handling of the bereavement exclusion controversy demonstrated the need for more inclusive deliberative processes in psychiatric classification. Scholars have argued that while the American Psychiatric Association may have legitimate authority over scientific questions, it lacks the same legitimacy when resolving what is ultimately a question of ethics and public policy. Who decides where normal ends and disorder begins? And who stands to benefit when that line moves?
The pharmaceutical industry does not benefit from people being told their grief is normal and will pass. It benefits from diagnostic categories that map neatly onto prescriptions. The DSM-5 itself is careful to note that recognizing major depression in the context of bereavement “by no means implies that antidepressant treatment is warranted.” But in real clinical settings, diagnosis and prescription have a habit of arriving together. The concern isn’t paranoid. It’s proportionate.
After sitting with all of this: the bereavement exclusion was a blunt instrument used to solve a real problem. The problem is that clinicians need to distinguish between normal grief and clinical illness in someone who is also bereaved. The exclusion didn’t solve that problem – it bypassed it. A categorical rule that says “no diagnosis before two months” doesn’t teach a clinician anything. It just defers the question.
What We Should Actually Be Arguing About
The grief-versus-depression debate has, for over a decade, been framed as a binary: either grief is sacred and untouchable by clinical language, or grief is just depression with a PR problem. Both framings are wrong.
Grief is real. It has its own arc, its own logic, its own strange rhythms – the way the third month is often harder than the first, the way ordinary Tuesdays become the place where it lives. None of that is a disorder. Most people who lose someone they love will go through it and come out the other side changed but intact.
But some won’t. The people who won’t weren’t being well served by a rule that said: wait two months, then we’ll see. A rule like that protects a concept – the idea of grief as sacred – more than it protects actual people. The grief depression diagnosis question is really a question about where clinical judgment should live. The answer is with trained clinicians, informed by the best available evidence, not with a calendar. The DSM-5 put it there. That was the right call.
The Harder Conversation
The debate over the bereavement exclusion gets most of the oxygen, but the harder, still-unresolved conversation is about what comes after the diagnosis. How do we train clinicians to use that judgment well? How do we guard against commercial pressures that push toward over-prescribing? How do we build a mental health system where diagnosis leads to the right treatment for the specific person, not a reflexive prescription?
Those problems didn’t start with the bereavement exclusion, and removing it didn’t solve them. But they’re the real stakes – not the diagnostic rule itself. Confusing a systemic failure in clinical culture with the question of whether the rule should exist is, ultimately, the central mistake the critics have been making all along. The exclusion gave clinicians a calendar to hide behind. Getting rid of it asked them to actually look at the person sitting in front of them. That’s not a flaw in the system. It’s what the system was always supposed to do.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.